Cancer therapeutic resistance

Cancer therapeutic resistance occurs as cancers develop resistance to treatments such as chemotherapy, radiotherapy and targeted therapies, through many different mechanisms. These include specific genetic and epigenetic changes in the cancer cell and/or the microenvironment in which the cancer cell resides.

Latest Research and Reviews

  • Research | | open

    • Sophie M. Stief
    • , Anna-Li Hanneforth
    • , Sabrina Weser
    • , Raphael Mattes
    • , Michela Carlet
    • , Wen-Hsin Liu
    • , Michael D. Bartoschek
    • , Helena Domínguez Moreno
    • , Matthias Oettle
    • , Julia Kempf
    • , Binje Vick
    • , Bianka Ksienzyk
    • , Belay Tizazu
    • , Maja Rothenberg-Thurley
    • , Hilmar Quentmeier
    • , Wolfgang Hiddemann
    • , Sebastian Vosberg
    • , Philipp A. Greif
    • , Klaus H. Metzeler
    • , Gunnar Schotta
    • , Sebastian Bultmann
    • , Irmela Jeremias
    • , Heinrich Leonhardt
    •  & Karsten Spiekermann
    Leukemia, 1-13
  • Research | | open

    Targeted inhibition of the ERK-MAPK pathway is challenged by the development of resistance and toxicity. Here, the authors show that SHOC2 genetic inhibition impairs lung tumour development and improves MEK inhibitor efficacy in RAS- and EGFR-mutant cells.

    • Greg G. Jones
    • , Isabel Boned del Río
    • , Sibel Sari
    • , Aysen Sekerim
    • , Lucy C. Young
    • , Nicole Hartig
    • , Itziar Areso Zubiaur
    • , Mona A. El-Bahrawy
    • , Rob E. Hynds
    • , Winnie Lei
    • , Miriam Molina-Arcas
    • , Julian Downward
    •  & Pablo Rodriguez-Viciana
  • Research | | open

    The BCL-2 mutation G101V reduces venetoclax affinity and confers drug resistance in patients with chronic lymphocytic leukaemia. Here, the authors present crystal structures and biochemical analyses of venetoclax bound to BCL-2 and the G101V mutant, revealing the structural basis for venetoclax resistance.

    • Richard W. Birkinshaw
    • , Jia-nan Gong
    • , Cindy S. Luo
    • , Daisy Lio
    • , Christine A. White
    • , Mary Ann Anderson
    • , Piers Blombery
    • , Guillaume Lessene
    • , Ian J. Majewski
    • , Rachel Thijssen
    • , Andrew W. Roberts
    • , David C. S. Huang
    • , Peter M. Colman
    •  & Peter E. Czabotar
  • Research |

    Coppé and colleagues design a peptide phosphorylation-screening system that simultaneously measures the enzymatic activity of multiple kinases, identifying mechanisms of therapy resistance and druggable targets in colorectal cancer and melanoma.

    • Jean-Philippe Coppé
    • , Miki Mori
    • , Bo Pan
    • , Christina Yau
    • , Denise M. Wolf
    • , Ana Ruiz-Saenz
    • , Diede Brunen
    • , Anirudh Prahallad
    • , Paulien Cornelissen-Steijger
    • , Kristel Kemper
    • , Christian Posch
    • , Changjun Wang
    • , Courtney A. Dreyer
    • , Oscar Krijgsman
    • , Pei Rong Evelyn Lee
    • , Zhongzhong Chen
    • , Daniel S. Peeper
    • , Mark M. Moasser
    • , René Bernards
    •  & Laura J. van ‘t Veer
    Nature Cell Biology 21, 778-790

News and Comment